, Volume 13, Issue 1, pp 38–56 | Cite as

Bone disease in anorexia nervosa

  • Anastasia D. DedeEmail author
  • George P. Lyritis
  • Symeon Tournis


Anorexia nervosa is a serious psychiatric disorder accompanied by high morbidity and mortality. It is characterized by emaciation due to self-starvation and displays a unique hormonal profile. Alterations in gonadal axis, growth hormone resistance with low insulin-like growth factor I levels, hypercortisolemia and low triiodothyronine levels are almost universally present and constitute an adaptive response to malnutrition. Bone metabolism is likewise affected resulting in low bone mineral density, reduced bone accrual and increased fracture risk. skeletal deficits often persist even after recovery from the disease with serious implications for future skeletal health. The pathogenetic mechanisms underlying bone disease are quite complicated and treatment is a particularly challenging task.

Key words

Anorexia nervosa Bone disease Fractures 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Psychiatric Association, 2013 Diagnostic and Statistical Manual of Mental Disorders, 5th editionGoogle Scholar
  2. 2.
    Smink FR, Van Hoeken D, Hoek HW, 2012 Epidemiology of eating disorders: Incidence, prevalence and mortality rates. Curr Psychiatry Rep 14: 406–414.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Hoek HW, Van Hoeken D, 2003 Review of the prevalence and incidence of eating disorders. Int J Eat Disord 34: 383–396.PubMedCrossRefGoogle Scholar
  4. 4.
    Bulik CM, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL, 2006 Prevalence, heritability and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry 63: 305–312.PubMedCrossRefGoogle Scholar
  5. 5.
    Herpertz-Dahlmann B, Seitz J, Konrad K, 2011 Aetiology of anorexia nervosa: from a “psychosomatic family model” to a neuropsychiatric disorder? Eur Arch Psychiatry Clin Neurosci 26: Suppl 2: 177–181.CrossRefGoogle Scholar
  6. 6.
    Galusca B, Zouch M, Germain N, et al, 2008 Constitutional thinness:Unusual human phenotype of low bone quality. J Clin Endocrinol Metab 93: 110–117.PubMedCrossRefGoogle Scholar
  7. 7.
    Woods SC, D’Alessio DA, 2008 Central control of body weight and appetite. J Clin Endocrinol Metab 93: Suppl 1: 37–50.CrossRefGoogle Scholar
  8. 8.
    Eckert ED, Pomeroy C, Raymond N, Kohler PF, Thuras P, Bowers CY, 1998 Leptin in anorexia nervosa. J Clin Endocrinol Metab 83: 791–795.PubMedGoogle Scholar
  9. 9.
    Misra M, Miller KK, Almazan C, et al, 2004 Hormonal and body composition predictors of soluble leptin receptor, leptin and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 89: 3486–3495.PubMedCrossRefGoogle Scholar
  10. 10.
    Audi L, Mantzoros CS, Vidal-Puiq A, Vargas D, Gussinye M, Carrascosa A, 1998 Leptin in relation to resumption of menses in women with anorexia nervosa. Mol Psychiatry 3: 544–547.PubMedCrossRefGoogle Scholar
  11. 11.
    Hebebrand J, Blum WF, Barth N, et al, 1997 Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Mol Psychiatry 2: 330–334.PubMedCrossRefGoogle Scholar
  12. 12.
    Misra M, Miller KK, Kuo K, et al, 2005 Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 289: E373–381.PubMedCrossRefGoogle Scholar
  13. 13.
    Modan-Moses D, Stein D, Pariente C, et al, 2007 Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab 92: 1843–1847.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Delporte ML, Brichard SM, Hermans MP, Beguin C, Lambert M, 2003 Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf) 58: 22–29.CrossRefGoogle Scholar
  15. 15.
    Pannacciulli N, Vettor R, Milan G, et al, 2003 Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 88: 1748–1752.PubMedCrossRefGoogle Scholar
  16. 16.
    Tagami T, Satoh N, Usui T, Yamada K, Shimatsu A, Kuzuya H, 2004 Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 89: 1833–1837.PubMedCrossRefGoogle Scholar
  17. 17.
    Wojcik MH, Meenaghan E, Lawson EA, Misra M, Klibanski A, Miller KK, 2010 Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone 46: 796–800.PubMedCrossRefGoogle Scholar
  18. 18.
    Shiiya T, Nakazato M, Mizuta M, et al, 2002 Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240–244.PubMedCrossRefGoogle Scholar
  19. 19.
    Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M, 2008 Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. J Clin Endocrinol Metab 93: 4418–4421.PubMedCrossRefGoogle Scholar
  20. 20.
    Misra M, Miller KK, Kuo K, et al, 2005 Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 289: E347–356.PubMedCrossRefGoogle Scholar
  21. 21.
    Nedvidkova J, Krykorkova I, Bartak V, et al, 2003 Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab 88: 1678–1682.PubMedCrossRefGoogle Scholar
  22. 22.
    Utz AL, Lawson EA, Misra M, et al, 2008 Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 43: 135–139.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Pfluger PT, Kampe J, Castaneda TR, et al, 2007 Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92: 583–588.PubMedCrossRefGoogle Scholar
  24. 24.
    Halmi KA, Sherman BM, 1975 Gonadotropin response to LH-RH in anorexia nervosa. Arch Gen Psychiatry 32: 875–878.PubMedCrossRefGoogle Scholar
  25. 25.
    Sherman BM, Halmi KA, Zamudio R, 1975 LH and FSH response to gonadotropin-releasing hormone in anorexia nervosa: Effect of nutritional rehabilitation. J Clin Endocrinol Metab 41: 135–142.PubMedCrossRefGoogle Scholar
  26. 26.
    Boyar RM, Katz J, Finkelstein JW, et al, 1974 Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. N Engl J Med 291: 861–865.PubMedCrossRefGoogle Scholar
  27. 27.
    Chou SH, Chamberland JP, Liu X, et al, 2011 Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA 108: 6585–6590.PubMedCrossRefGoogle Scholar
  28. 28.
    Köpp W, Blum WF, von Prittwitz S, et al, 1997 Low leptin levels predict amenorrhea in underweight and eating disordered females. Mol Psychiatry 2: 335–340.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Kluge M, Schüssler P, Schmidt D, Uhr M, Steiger A, 2012 Ghrelin suppresses secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in women. J Clin Endocrinol Metab 97: E448–451.PubMedCrossRefGoogle Scholar
  30. 30.
    Kluge M, Schüssler P, Uhr M, Yassouridis A, Steiger A, 2007 Ghrelin suppresses secretion of luteinizing hormone in humans. J Clin Endocrinol Metab 92: 3202–3205.PubMedCrossRefGoogle Scholar
  31. 31.
    Misra M, Katzman DK, Cord J, et al, 2008 Bone metabolism in adolescent boys with anorexia nervosa. J Clin Endocrinol Metab 93: 3029–3036.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Tomova A, Kumanov P, 1999 Sex differences and similarities of hormonal alterations in patients with anorexia nervosa. Andrologia 31: 143–147.PubMedCrossRefGoogle Scholar
  33. 33.
    Miller KK, Lawson EA, Mathur V, et al, 2007 Androgens in women with anorexia nervosa and normal weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 92: 1334–1339.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Estour B, Germain N, Diconne E, et al, 2010 Hormonal profile heterogeneity and short-term physical risk in restrictive anorexia nervosa. J Clin Endocrinol Metab 95: 2203–2210.PubMedCrossRefGoogle Scholar
  35. 35.
    Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH, Leboff MS, 1999 Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res 14: 136–145.PubMedCrossRefGoogle Scholar
  36. 36.
    Støving RK, Veldhuis JD, Flyvbjerg A, et al, 1999 Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: Indirect evidence for disruption of feedback regulation within the GH-Insulin-like growth factor I axis. J Clin Endocrinol Metab 84: 2056–2063.PubMedGoogle Scholar
  37. 37.
    Misra M, Miller KK, Bjornson J, et al, 2003 Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 88: 5615–5623.PubMedCrossRefGoogle Scholar
  38. 38.
    De Rosa G, Corsello SM, De Rosa E, et al, 1983 Endocrine study of anorexia nervosa. Exp Clin Endocrinol 82: 160–172.PubMedCrossRefGoogle Scholar
  39. 39.
    Masuda A, Shibasaki T, Hotta M, Suematsu H, Shizume K, 1988 Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion. J Endocrinol Invest 11: 297–302.PubMedCrossRefGoogle Scholar
  40. 40.
    Argente J, Caballo N, Barrios V, et al, 1997 Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effect of short and long term weight recuperation. J Clin Endocrinol Metab 82: 2084–2092.PubMedGoogle Scholar
  41. 41.
    Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K, 2000 The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 85: 200–206.PubMedGoogle Scholar
  42. 42.
    Støving RK, Chen JW, Glintborg D, et al, 2007 Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. J Clin Endocrinol Metab 92: 2323–2329.PubMedCrossRefGoogle Scholar
  43. 43.
    Fazeli PK, Lawson E, Prabhakaran R, et al, 2010 Effects of recombinant human growth hormone in anorexia nervosa: A randomized, placebo-controlled study. J Clin Endocrinol Metab 65: 4889–4897.CrossRefGoogle Scholar
  44. 44.
    Gold PW, Gwirtsman H, Avgerinos PC, et al, 1986 Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 314: 1335–1342.PubMedCrossRefGoogle Scholar
  45. 45.
    Misra M, Miller KK, Almazan C, et al, 2004 Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 89: 4972–4980.PubMedCrossRefGoogle Scholar
  46. 46.
    Lawson EA, Donoho D, Miller KK, et al, 2009 Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J Clin Endocrinol Metab 94: 4710–4716.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Lawson EA, Holsen LM, Desanti R, et al, 2013 Increased hypothalamic-pituitary-adrenal drive is associated with decreased appetite and hypoactivation of food motivation neurocircuitry in anorexia nervosa. Eur J Endocrinol 169: 639–647.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Onur S, Haas V, Bosy-Westphal A, et al, 2005 L-triiodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur J Endocrinol 152: 179–184.PubMedCrossRefGoogle Scholar
  49. 49.
    Leslie RD, Isaacs AJ, Gomez J, Raggatt PR, Bayliss R, 1978 Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain. Br Med J 2: 526–528.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Croxson MS, Ibbertson HK, 1977 Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. J Clin Endocrinol Metab 44: 167–174.PubMedCrossRefGoogle Scholar
  51. 51.
    Bannai C, Kuzuya N, Koide Y, et al, 1988 Assessment of the relationship between serum thyroid hormone levels and peripheral metabolism in patients with anorexia nervosa. Endocrinol Jpn 35: 455–462.PubMedCrossRefGoogle Scholar
  52. 52.
    Giustina A, Mazzioti G, Canalis E, 2008 Growth hormone, insulin-like growth factors and the skeleton. Endocr Rev 29: 535–559.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Nussbaum M, Baird D, Sonnenblick M, Cowan K, Shenker IR, 1985 Short stature in anorexia nervosa patients. J Adolesc Health Care 6: 453–455.PubMedCrossRefGoogle Scholar
  54. 54.
    Modan-Moses D, Yaroslavsky A, Novikov I, et al, 2003 Stunting of growth as a major feature of anorexia nervosa in male adolescents. Pediatrics 111: 270–276.PubMedCrossRefGoogle Scholar
  55. 55.
    Modan-Moses D, Yaroslavsky A, Kochavi B, et al, 2012 Linear growth and final adult height characteristics in adolescent females with anorexia nervosa. PLoS One 7: e45504.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Prabhakaran R, Misra M, Miller KK, et al, 2008 Determinants of height in adolescent girls with anorexia nervosa. Pediatrics 121: e1517–1523.PubMedCrossRefGoogle Scholar
  57. 57.
    Lantzouni E, Frank GR, Golden NH, Shenker RI, 2002 Reversibility of growth stunting in early onset anorexia nervosa: a prospective study. J Adolesc Health 31: 162–165.PubMedCrossRefGoogle Scholar
  58. 58.
    Rozé C, Doyen C, Le Heuzey MF, Armoogum P, Mouren MC, Léger J, 2007 Predictors of late menarche and adult height in children with anorexia nervosa. Clin Endocrinol 67: 462–467.CrossRefGoogle Scholar
  59. 59.
    Grinspoon S, Thomas E, Pitts S, et al, 2000 Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 133: 790–794.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Soyka LA, Grinspoon S, Levitsky LL, Herzog DB, Klibanski A, 1999 The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84: 4489–4496.PubMedGoogle Scholar
  61. 61.
    Mehler PS, Sabel AL, Watson T, Andersen AE, 2008 High risk of osteoporosis in male patients with eating disorders. Int J Eat Disord 41: 666–672.PubMedCrossRefGoogle Scholar
  62. 62.
    Lawson EA, Miller KK, Bredella MA, et al, 2010 Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone 46: 458–463.PubMedCrossRefGoogle Scholar
  63. 63.
    Resch H, Newrkla S, Grampp S, et al, 2000 Ultrasound and X-ray based bone densitometry in patients with anorexia nervosa. Calcif Tissue Int 66: 338–341.PubMedCrossRefGoogle Scholar
  64. 64.
    Winston AP, Alwazeer AE, Bankart MJ, 2008 Screening for osteoporosis in anorexia nervosa: prevalence and predictors of reduced bone mineral density. Int J Eat Disord 41: 284–287.PubMedCrossRefGoogle Scholar
  65. 65.
    Miller KK, Lee EE, Lawson EA, et al, 2006 Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab 91: 2931–2937.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Trombetti A, Richert L, Herrmann FR, Chevalley T, Graf JD, Rizzoli R, 2013 Selective determinants of low bone mineral mass in adult women with anorexia nervosa. Int J Endocrinol 2013: 897193.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Biller BM, Saxe V, Herzog DB, Rosenthal DI, Holzman S, Klibanski A, 1989 Mechanisms of osteoporosis in adult women with anorexia nervosa. J Clin Endocrinol Metab 68: 548–554.PubMedCrossRefGoogle Scholar
  68. 68.
    Misra M, Aggarwal A, Miller KK, et al, 2004 Effects of anorexia nervosa on clinical, hematologic, biochemical and bone density parameters in community-dwelling adolescent girls. Pediatrics 114: 1574–1583.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Bachrach LK, Guido D, Katzman D, Litt IF, Marcus R, 1990 Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 86: 440–447.PubMedGoogle Scholar
  70. 70.
    Soyka LA, Misra M, Frenchman A, et al, 2002 Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 87: 4177–4185.PubMedCrossRefGoogle Scholar
  71. 71.
    Klibanski A, Biller BMK, Schoenfeld DA, Herzog DB, Saxe VC, 1995 The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 80: 898–904.PubMedGoogle Scholar
  72. 72.
    Seeman E, Karlsson MK, Duan Y, 2000 On exposure to anorexia nervosa, the temporal variation in axial and appendicular skeletal development predisposes to site-specific deficits in bone size and density: a cross-sectional study. J Bone Miner Res 15: 2259–2265.PubMedCrossRefGoogle Scholar
  73. 73.
    Karlsson MK, Weigall SJ, Duan Y, Seeman E, 2000 Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. J Clin Endocrinol Metab 85: 3177–3182.PubMedCrossRefGoogle Scholar
  74. 74.
    Bredella MA, Misra M, Miller KK, et al, 2008 Distal radius in adolescent girls with anorexia nervosa: Trabecular structure analysis with High-Resolution Flat-Panel volume CT. Radiology 249: 938–946.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Faje AT, Karim L, Taylor A, et al, 2013 Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius. J Clin Endocrinol Metab 98: 1923–1929.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Milos G, Spindler A, Rüegsegger P, et al, 2005 Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos Int 16: 783–790.PubMedCrossRefGoogle Scholar
  77. 77.
    Walsh CJ, Phan CM, Misra M, et al, 2010 Women with anorexia nervosa: Finite element and trabecular structure analysis by using Flat Panel volume CT. Radiology 257: 167–174.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Hartman D, Crisp A, Rooney B, Rackow C, Atkinson R, Patel S, 2000 Bone density of women who have recovered from anorexia nervosa. Int J Eat Disord 28: 107–112.PubMedCrossRefGoogle Scholar
  79. 79.
    Herzog W, Minne H, Deter C, et al, 1993 Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J Bone Miner Res 8: 597–605.PubMedCrossRefGoogle Scholar
  80. 80.
    Halvorsen I, Platou D, Høiseth A, 2012 Bone mass eight years after treatment for adolescent-onset anorexia nervosa. Eur Eat Disord Rev 20: 386–392.PubMedCrossRefGoogle Scholar
  81. 81.
    Wentz E, Mellström D, Gillberg C, Sundh V, Gillberg IC, Råstam M, 2003 Bone density 11 years after anorexia nervosa onset in a controlled study of 39 cases. Int J Eat Disord 34: 314–318.PubMedCrossRefGoogle Scholar
  82. 82.
    Ostrowska Z, Ziora K, Oswiecimska J, et al, 2012 RANKL/RANK/OPG system and bone status in females with anorexia nervosa. Bone 50: 156–160.PubMedCrossRefGoogle Scholar
  83. 83.
    Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A, 1996 Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81: 3864–3870.PubMedGoogle Scholar
  84. 84.
    Weinbrenner T, Zittermann A, Gouni-Berthold I, Stehle P, Berthold HK, 2003 Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. Eur J Clin Nutr 57: 1262–1267.PubMedCrossRefGoogle Scholar
  85. 85.
    Lennkh C, De Zwaan M, Bailer U, et al, 1999 Osteopenia in anorexia nervosa: specific mechanisms of bone loss. J Psychiatr Res 33: 349–356.PubMedCrossRefGoogle Scholar
  86. 86.
    Legroux-Gerot I, Vignau J, D’Herbomez M, et al, 2007 Evaluation of bone loss and its mechanisms in anorexia nervosa. Calcif Tissue Int 81: 174–182.PubMedCrossRefGoogle Scholar
  87. 87.
    Faje AT, Fazeli PK, Katzman DK, et al, 2012 Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone 51: 474–479.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Misra M, Katzman DK, Clarke H, et al, 2013 Hip structural analysis in adolescent boys with anorexia nervosa and controls. J Clin Endocrinol Metab 98: 2952–2958.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    DiVasta AD, Beck TJ, Petit MA, Feldman HA, LeBoff MS, Gordon CM, 2007 Bone cross-sectional geometry in adolescents and young women with anorexia nervosa: a hip structural analysis study. Osteoporos Int 18: 797–804.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD, 2007 Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: The OFELY study. J Bone Miner Res 22: 425–433.PubMedCrossRefGoogle Scholar
  91. 91.
    Divasta AD, Feldman HA, Gordon CM, 2013 Vertebral fracture assessment in adolescents and young women with anorexia nervosa: A Case series. J Clin Densitom 17: 207–211.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR, 1991 The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 265: 1133–1138.PubMedCrossRefGoogle Scholar
  93. 93.
    Lucas RA, Melton J, Crowson CS, O’Fallon WM, 1999 Long-term fracture risk among women with anorexia nervosa: A population-based cohort study. Mayo Clin Proc 74: 972–977.PubMedCrossRefGoogle Scholar
  94. 94.
    Vestergaard P, Emborg C, Støving RK, Hagen C, Mosekilde L, Brixen K, 2002 Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders-a nationwide register study. Int J Eat Disord 32: 301–308.PubMedCrossRefGoogle Scholar
  95. 95.
    Chow J, Tobias JH, Colston KW, Chambers TJ, 1992 Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 89: 74–78.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Majeska RJ, Ryaby JT, Einhorn TA, 1994 Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg Am 76: 713–721.PubMedCrossRefGoogle Scholar
  97. 97.
    Qu Q, Perälä-Heape M, Kapanen A, et al, 1998 Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22: 201–209.PubMedCrossRefGoogle Scholar
  98. 98.
    Ferrari S, Bianchi ML, Eisman JA, et al; IOF Committee of scientific Advisors Working Group on Osteoporosis Pathophysiology, 2012, Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23: 2735–2748.PubMedCrossRefGoogle Scholar
  99. 99.
    Grinspoon S, Miller K, Coyle C, et al, 1999 Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 84: 2049–2055.PubMedGoogle Scholar
  100. 100.
    Kasperk C, Fitzsimmons R, Strong D, 1990 Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 71: 1322–1329.PubMedCrossRefGoogle Scholar
  101. 101.
    O’Brien CA, Jia D, Plotkin LI, et al, 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145: 1835–1841.PubMedCrossRefGoogle Scholar
  102. 102.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC, 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274–282.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Jia D, O’Brien CA, Stewart SA, Manolagas SC, Weinstein RS, 2006 Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147: 5592–5599.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al, 2013 Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 98: 2277–2284.PubMedCrossRefGoogle Scholar
  105. 105.
    van Staa TP, Leufkens HG, Cooper C, 2002 The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777–787.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    McCarthy TL, Centrella M, Canalis E, 1989 Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124: 301–309.PubMedCrossRefGoogle Scholar
  107. 107.
    Sims NA, Clément-Lacroix P, Da Ponte F, et al, 2000 Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of stat5. J Clin Invest 106: 1095–1103PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Pereira RC, Jorgetti V, Canalis E, 1999 Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts. Am J Physiol 277: E496–504.PubMedGoogle Scholar
  109. 109.
    Gouveia CH, Schultz JJ, Bianco AC, Brent GA, 2001 Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J Endocrinol 170: 667–675.PubMedCrossRefGoogle Scholar
  110. 110.
    Varga F, Rumpler M, Zoehrer R, et al, 2010 T3 affects expression of collagen I and collagen cross-linking in bone cell cultures. Biochem Biophys Res Commun 402: 180–185.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Eriksen EF, Mosekilde L, Melsen F, 1986 Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone 7: 101–108.PubMedCrossRefGoogle Scholar
  112. 112.
    Vestergaard P, Mosekilde L, 2002 Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12: 411–419.PubMedCrossRefGoogle Scholar
  113. 113.
    Vestergaard P, Rejnmark L, Mosekilde L, 2005 Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 77: 139–144.PubMedCrossRefGoogle Scholar
  114. 114.
    Ravn P, Cizza G, Bjarnason NH, et al, 1999 Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. J Bone Miner Res 14: 1622–1627.PubMedCrossRefGoogle Scholar
  115. 115.
    De Laet C, Kanis JA, Odén A, et al, 2005 Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int 16: 1330–1338.PubMedCrossRefGoogle Scholar
  116. 116.
    Dalsky GP, Stocke KS, Ehsani AA, Slatopolsky E, Lee WC, Birge SJ Jr 1988 Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 108: 824–828.PubMedCrossRefGoogle Scholar
  117. 117.
    Snow CM, Williams DP, LaRiviere J, Fuchs RK, Robinson TL, 2001 Bone gains and losses follow seasonal training and detraining in gymnasts. Calcif Tissue Int 69: 7–12.PubMedCrossRefGoogle Scholar
  118. 118.
    Pettersson U, Nordström P, Alfredson H, Henriksson-Larsén K, Lorentzon R, 2000 Effect of high impact activity on bone mass and size in adolescent females: A comparative study between two different types of sports. Calcif Tissue Int 67: 207–214.PubMedCrossRefGoogle Scholar
  119. 119.
    Zerwekh JE, Ruml LA, Gottschalk F, Pak CY, 1998 The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res 13: 1594–601.PubMedCrossRefGoogle Scholar
  120. 120.
    Leblanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM, 1990 Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 5: 843–850.PubMedCrossRefGoogle Scholar
  121. 121.
    Ellman R, Spatz J, Cloutier A, Palme R, Christiansen BA, Bouxsein ML, 2013 Partial reductions in mechanical loading yield proportional changes in bone density, bone architecture, and muscle mass. J Bone Miner Res 28: 875–885.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Fleischer J, Stein EM, Bessler M, et al, 2008 The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 93: 3735–3740.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Vilarrasa N, Gómez JM, Elio I, et al, 2009 Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg 19: 860–866.PubMedCrossRefGoogle Scholar
  124. 124.
    Tatsumi S, Ishii K, Amizuka N, et al, 2007 Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5: 464–475.PubMedCrossRefGoogle Scholar
  125. 125.
    Aguirre JI, Plotkin LI, Stewart SA, et al, 2006 Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 21: 605–615.PubMedCrossRefGoogle Scholar
  126. 126.
    Bonewald LF, Johnson ML, 2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42: 606–615.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Lin C, Jiang X, Dai Z, et al, 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24: 651–1661.CrossRefGoogle Scholar
  128. 128.
    Spatz JM, Ellman R, Cloutier AM, et al, 2013 Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res 28: 865–874.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Gaudio A, Pennisi P, Bratengeier C, et al, 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95: 2248–2253.PubMedCrossRefGoogle Scholar
  130. 130.
    Spatz JM, Fields EE, Yu EW, et al, 2012 Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab 97: E1736–1740.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Armamento-Villareal R, Sadler C, Napoli N, et al, 2012 Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res 27: 1215–1221.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Kooh SW, Noriega E, Leslie K, Müller C, Harrison JE, 1996 Bone mass and soft tissue composition in adolescents with anorexia nervosa. Bone 19: 181–188.PubMedCrossRefGoogle Scholar
  133. 133.
    Kosmiski L, Schmiege SJ, Mascolo M, Gaudiani J, Mehler PS, 2013 Chronic starvation secondary to anorexia nervosa is associated with an adaptive suppression of resting energy expenditure. J Clin Endocrinol Metab [DOI:]
  134. 134.
    Haas VK, Kohn MR, Clarke SD, et al, 2009 Body composition changes in female adolescents with anorexia nervosa. Am J Clin Nutr 89: 1005–1010.PubMedCrossRefGoogle Scholar
  135. 135.
    McLoughlin DM, Spargo E, Wassif WS, et al, 1998 Structural and functional changes in skeletal muscle in anorexia nervosa. Acta Neuropathol 95: 632–640.PubMedCrossRefGoogle Scholar
  136. 136.
    Essén B, Fohlin L, Thorén C, Saltin B, 1981 Skeletal muscle fibre types and sizes in anorexia nervosa patients. Clin Physiol 1: 395–403.PubMedCrossRefGoogle Scholar
  137. 137.
    Lindboe CF, Askevold F, Slettebø M, 1982 Changes in skeletal muscles of young women with anorexia nervosa. An enzyme histochemical study. Acta Neuropathol 56: 299–302.PubMedCrossRefGoogle Scholar
  138. 138.
    Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL, 1999 Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140: 1630–1638.PubMedCrossRefGoogle Scholar
  139. 139.
    Cornish J, Callon KE, Bava U, et al, 2002 Leptin directly stimulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175: 405–415.PubMedCrossRefGoogle Scholar
  140. 140.
    Ducy P, Amling M, Takeda S, et al, 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197–207.CrossRefPubMedGoogle Scholar
  141. 141.
    Pasco JA, Henry MJ, Kotowicz MA, et al, 2001 Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86: 1884–1887.PubMedGoogle Scholar
  142. 142.
    Yamauchi M, Sugimoto T, Yamaguchi T, et al, 2001 Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 55: 341–347.CrossRefGoogle Scholar
  143. 143.
    Ruhl CE, Everhart JE, 2002 Relationship of serum leptin concentrations with bone mineral density in the United states population. J Bone Miner Res 17: 1896–1903.PubMedCrossRefGoogle Scholar
  144. 144.
    Odabaşi E, Ozata M, Turan M, et al, 2000 Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol 142: 170–173.PubMedCrossRefGoogle Scholar
  145. 145.
    Berner HS, Lyngstadaas SP, Spahr A, et al, 2004 Adiponectin and its receptors are expressed in bone-forming cells. Bone 35: 842–849.PubMedCrossRefGoogle Scholar
  146. 146.
    Shinoda Y, Yamaguchi M, Ogata N, et al, 2006 Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99: 196–208.PubMedCrossRefGoogle Scholar
  147. 147.
    Oshima K, Nampei A, Matsuda M, et al, 2005 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331: 520–526.PubMedCrossRefGoogle Scholar
  148. 148.
    Biver E, Salliot C, Combescure C, et al, 2011 Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 96: 2703–2713.PubMedCrossRefGoogle Scholar
  149. 149.
    Misra M, Miller KK, Cord J, et al, 2007 Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab 92: 2046–2052.PubMedCrossRefGoogle Scholar
  150. 150.
    Baldock PA, Sainsbury A, Couzens M, et al, 2002 Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109: 915–921.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Baldock PA, Lee NJ, Driessler F, et al, 2009 Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLos One 4: e8415.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Wong IP, Nguyen AD, Khor EC, et al, 2013 Neuropeptide Y is a critical modulator of leptin’s regulation of cortical bone. J Bone Miner Res 28: 886–898.PubMedCrossRefGoogle Scholar
  153. 153.
    Wortley KE, Garcia K, Okamoto H, et al, 2007 Peptide YY regulates bone turnover in rodents. Gastroenterology 133: 1534–1543.PubMedCrossRefGoogle Scholar
  154. 154.
    Wong IP, Driessler F, Khor EC, et al, 2012 Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLos One 7: e40038.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Misra M, Miller KK, Tsai P, et al, 2006 Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 91: 1027–1033.PubMedCrossRefGoogle Scholar
  156. 156.
    Cornish J, Callon KE, Cooper GJ, Reid IR, 1995 Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 207: 133–139.PubMedCrossRefGoogle Scholar
  157. 157.
    Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR, 2001 Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29: 162–168.PubMedCrossRefGoogle Scholar
  158. 158.
    Cornish J, Callon KE, King AR, Cooper GJ, Reid IR, 1998 Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 275: E694–699.PubMedGoogle Scholar
  159. 159.
    Bollag RJ, Zhong Q, Phillips P, et al, 2000 Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141: 1228–1235.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Xie D, Cheng H, Hamrick M, et al, 2005 Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37: 759–769.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Bollag RJ, Zhong Q, Ding KH, et al, 2001 Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 177: 35–41.PubMedCrossRefGoogle Scholar
  162. 162.
    Maccarinelli G, Sibilia V, Torsello A, et al, 2005 Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 184: 249–256.PubMedCrossRefGoogle Scholar
  163. 163.
    Fukushima N, Hanada R, Teranishi H, et al, 2005 Ghrelin directly regulates bone formation. J Bone Miner Res 20: 790–798.PubMedCrossRefGoogle Scholar
  164. 164.
    Sun Y, Ahmed S, Smith RG, 2003 Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23: 7973–7981.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Misra M, Miller KK, Stewart V, et al, 2005 Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. J Clin Endocrinol Metab 90: 5082–5087.PubMedCrossRefGoogle Scholar
  166. 166.
    Fazeli PK, Galder GL, Miller KK, et al, 2012 Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord 45: 970–976.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Diem SJ, Blackwell TL, Stone KL, et al, 2007 Use of antidepressants and rates of hip bone loss in elderly women: the study of osteoporotic fractures. Arch Intern Med 167: 1240–1245.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Haney EM, Chan BK, Diem SJ, et al, Osteoporotic Fractures in Men study Group 2007 Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167: 1246–1251.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Richards JB, Papaioannou A, Adachi JD, et al, Canadian Multicentre Osteoporosis study Research Group 2007 Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167: 188–194.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z, 2002 Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156: 696–701.PubMedCrossRefGoogle Scholar
  171. 171.
    Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH, 2005 Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146: 685–693.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Ross AC, Manson JE, Abrams SA, et al, 2011 The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 96: 53–58.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A, 2005 Medical findings in outpatients with anorexia nervosa. Arch Intern Med 165: 561–566.PubMedCrossRefGoogle Scholar
  174. 174.
    Haagensen AL, Feldman HA, Ringelheim J, Gordon CM, 2008 Low prevalence of vitamin D deficiency among adolescents with anorexia nervosa. Osteoporos Int 19: 289–294.PubMedCrossRefGoogle Scholar
  175. 175.
    Morgan JF, Bolton J, Sedgwick PM, Patel S, Lacey JH, Conway GS, 1999 Changes in plasma concentrations of leptin and body fat composition during weight restoration in anorexia nervosa. J Clin Endocrinol Metab 84: 2257.PubMedCrossRefGoogle Scholar
  176. 176.
    Bolton JG, Patel S, Lacey JH, White S, 2005 A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa. Osteoporos Int 16: 1955–1962.PubMedCrossRefGoogle Scholar
  177. 177.
    Dominguez J, Goodman L, Sen Gupta S, et al, 2007 Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. Am J Clin Nutr 86: 92–99.PubMedCrossRefGoogle Scholar
  178. 178.
    Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB, 1992 The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 75: 762–767.PubMedGoogle Scholar
  179. 179.
    Viapiana O, Gati D, Dalle Grave R, et al, 2007 Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Bone 40: 1073–1077.PubMedCrossRefGoogle Scholar
  180. 180.
    Augusseau AC, Lafage-Proust MH, Margaillan P, et al, 2000 Weight gain reverses bone turnover and restores circadian variation of bone resoption in anorexic patients. Clin Endocrinol 52: 113–121.CrossRefGoogle Scholar
  181. 181.
    Heer M, Mika C, Grzella I, Drummer C, Herpertz-Dahlmann B, 2002 Changes in bone turnover in patients with anorexia nervosa during eleven weeks of inpatient dietary treatment. Clin Chem 48: 754–760.PubMedGoogle Scholar
  182. 182.
    Compston JE, McConachie C, Stott C, et al, 2006 Changes in bone mineral density, body composition and biochemical markers of bone turnover during weight gain in adolescents with severe anorexia nervosa: a 1-year prospective study. Osteoporos Int 17: 77–84.PubMedCrossRefGoogle Scholar
  183. 183.
    Milos G, Spindler A, Rüegsegger P, et al, 2007 Does weight gain induce cortical and trabecular bone regain in anorexia nervosa? A two-year prospective study. Bone 41: 869–874.PubMedCrossRefGoogle Scholar
  184. 184.
    García-De Alvaro MT, Muñoz-Calvo MT, Martínez G, Barrios V, Hawkins F, Argente J, 2007 Regional skeletal bone deficit in female adolescents with anorexia nervosa: influence of the degree of malnutrition and weight recovery in a two year longitudinal study. J Pediatr Endocrinol Metab 20: 1223–1231.PubMedCrossRefGoogle Scholar
  185. 185.
    Misra M, Prabhakaran R, Miller KK, et al, 2008 Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 93: 1231–1237.PubMedCrossRefGoogle Scholar
  186. 186.
    Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R, 1992 Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res 7: 1467–1474.PubMedCrossRefGoogle Scholar
  187. 187.
    Gordon CM, Goodman E, Emans SJ, et al, 2002 Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 141: 64–70.PubMedCrossRefGoogle Scholar
  188. 188.
    Diamanti A, Bizzarri C, Gambarara M, et al, 2007 Bone mineral density in adolescent girls with early onset of anorexia nervosa. Clin Nutr 26: 329–334.PubMedCrossRefGoogle Scholar
  189. 189.
    Hay PJ, Delahunt JW, Hall A, Mitchell AW, Harper G, Salmond C, 1992 Predictors of osteopenia in premenopausal women with anorexia nervosa. Calcif Tissue Int 50: 498–501.PubMedCrossRefGoogle Scholar
  190. 190.
    Joyce JM, Warren DL, Humphries LL, Smith AJ, Coon JS, 1990 Osteoporosis in women with eating disorders: comparison of physical parameters, exercise, and menstrual status with SPA and DPA evaluation. J Nucl Med 31: 325–331.PubMedGoogle Scholar
  191. 191.
    Waugh EJ, Woodside DB, Beaton DE, Coté P, Hawker GA, 2011 Effects of exercise on bone mass in young women with anorexia nervosa. Med Sci Sports Exerc 43: 755–763.PubMedCrossRefGoogle Scholar
  192. 192.
    Legroux-Gerot I, Vignau J, Collier F, Cortet B, 2008 Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy. Calcif Tissue Int 83: 315–323.PubMedCrossRefGoogle Scholar
  193. 193.
    Muñoz MT, Morandé G, García-Centenera JA, Hervás F, Pozo J, Argente J, 2002 The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 146: 45–50.PubMedCrossRefGoogle Scholar
  194. 194.
    Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker R, 2002 The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 15: 135–143.PubMedCrossRefGoogle Scholar
  195. 195.
    Strokosch GR, Friedman AJ, Wu SC, Kamin M, 2006 Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health 39: 819–827.PubMedCrossRefGoogle Scholar
  196. 196.
    Misra M, Katzman D, Miller KK, et al, 2011 Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 26: 2430–2438.PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    Bloch M, Ish-Shalom S, Greenman Y, Klein E, Latzer Y, 2012 Dehydroepiandrosterone treatment effects on weight, bone density, bone metabolism and mood in women suffering from anorexia nervosa-a pilot study. Psychiatry Res 200: 544–549.PubMedCrossRefGoogle Scholar
  198. 198.
    Gordon CM, Grace E, Emans SJ, et al, 2002 Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: A randomized trial. J Clin Endocrinol Metab 87: 4935–4941.PubMedCrossRefGoogle Scholar
  199. 199.
    DiVasta AD, Feldman HA, Giancaterino C, Rosen CJ, LeBoff Ms, Gordon CM, 2012 The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism 61: 1010–1020.PubMedPubMedCentralCrossRefGoogle Scholar
  200. 200.
    Divasta AD, Feldman HA, Beck TJ, Leboff MS, Gordon CM, 2013 Does hormone replacement normalize bone geometry in adolescents with anorexia nervosa? J Bone Miner Res 29: 151–157.CrossRefGoogle Scholar
  201. 201.
    Nakahara T, Nagai N, Tanaka M, et al, 2006 The effects of bone therapy on tibial bone loss in young women with anorexia nervosa. Int J Eat Disord 39: 20–26.PubMedCrossRefGoogle Scholar
  202. 202.
    Golden NH, Iglesias EA, Jacobson MS, et al, 2005 Alendronate for the treatment of osteopenia in anorexia nervosa: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90: 3179–3185.PubMedCrossRefGoogle Scholar
  203. 203.
    Miller KK, Griego KA, Mulder J, et al, 2004 Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 89: 3903–3906.PubMedCrossRefGoogle Scholar
  204. 204.
    Miller KK, Meenaghan E, Lawson EA, et al, 2011 Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: A randomized, placebo-controlled study. J Clin Endocrinol Metab 96: 2081–2088.PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Misra M, McGrane J, Miller KK, et al, 2009 Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone 45: 493–498.PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A, 2002 Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87: 2883–2891.PubMedCrossRefGoogle Scholar
  207. 207.
    Iketani T, Kiriike N, Murray, et al, 2003 Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. Psychiatry Res 117: 259–269.PubMedCrossRefGoogle Scholar
  208. 208., assessed at 22/10/2013.

Copyright information

© Hellenic Endocrine Society 2014

Authors and Affiliations

  • Anastasia D. Dede
    • 1
    • 4
    Email author
  • George P. Lyritis
    • 2
  • Symeon Tournis
    • 3
  1. 1.Department of Endocrinology and MetabolismHippokrateion General HospitalAthensGreece
  2. 2.Hellenic Osteoporosis FoundationUniversity of Athens, KAT HospitalAthensGreece
  3. 3.Laboratory for Research of Musculoskeletal System “Theodoros Garofalidis”University of Athens, KAT HospitalAthensGreece
  4. 4.AthensGreece

Personalised recommendations